参考文献/References:
［1］ Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection［J］. Ann Surg, 2008, 248: 84- 96.
［2］ Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?［J］. J Hepatol, 2004, 40: 472- 477.
［3］ Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative- intent surgical resection［J］. Ann Surg Oncol, 2016, 23: 235- 243.
［4］ Song SC, Heo JS, Choi DW, et al. Survival benefits of surgical resection in recurrent cholangiocarcinoma［J］. J Korean Surg Soc, 2011, 81: 187- 194.
［5］ Shimada K, Sano T, Sakamoto Y, et al. Surgical outcomes of the mass- forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass- forming type of intrahepatic cholangiocarcinoma［J］. World J Surg, 2007, 31: 2016- 2022.
［6］ Shimizu J, Dono K, Nagai K, et al. A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy［J］. Gan To Kagaku Ryoho, 2011, 38: 2469- 2471.
［7］ Kurosaki I, Hatakeyama K. Repeated hepatectomy for recurrent intrahepatic cholangiocarcinoma: report of two cases［J］. Eur J Gastroenterol Hepatol, 2005, 17: 125- 130.
［8］ Ohtsuka M, Kimura F, Shimizu H, et al. Significance of repeated resection for recurrent intrahepatic cholangiocarcinoma［J］. Hepato- gastroenterology, 2009, 56: 1- 5.
［9］ Zhang SJ, Hu P, Wang N, et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma［J］. Ann Surg Oncol, 2013, 20: 3596- 3602.
［10］ Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long- term results and prognostic factors［J］. Ann Surg Oncol, 2007, 14: 2319- 2329.
［11］ Lin SM. Recent advances in radiofrequency ablation in the treatment of hepatocellular carcinoma and metastatic liver cancers［J］. Chang Gung Med J, 2009, 32: 22- 32.
［12］ Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma［J］. J Hepatol, 2014, 60: 1268- 1289.
［13］ Carrafiello G, Lagana D, Cotta E, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience［J］. Cardiovasc Intervent Radiol, 2010, 33: 835- 839.
［14］ 张德东， 于晓玲， 梁 萍， 等． 经皮微波消融治疗肝内胆管细胞癌的疗效分析［J］． 中华医学超声杂志?电子版， 2011， 8： 2314- 2319．
［15］ Fu Y, Yang W, Wu W, et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma［J］. J Vasc Interv Radiol, 2012, 23: 642- 649.
［16］ Giorgio A, Calisti G, de Stefano G, et al. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience［J］. Anticancer Res, 2011, 31: 4575- 4580.
［17］ 王 燕， 徐辉雄， 吕明德， 等． 超声引导经皮热消融治疗肝内胆管细胞癌［J］． 中华肝胆外科杂志， 2011， 17： 539- 542．
［18］ Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma［J］. AJR Am J Roentgenol, 2011, 196: W205- W209.
［19］ Han K, Ko HK, Kim KW, et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma : syste- matic review and meta- analysis［J］. J Vasc Interv Radiol, 2015, 26: 943- 948.
［20］ Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepato- cellular carcinoma［J］. Hepatology, 2002, 35: 1164- 1171.
［21］ Park BK, Paik YH, Park JY, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor- C in intrahepatic cholangiocarcinoma［J］. Am J Clin Oncol, 2006, 29: 138- 142.
［22］ Park SY, Kim JH, Yoon HJ, et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma［J］. Clin Radiol, 2011, 66: 322- 328.
［23］ Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma［J］. J Surg Oncol, 2015, 111: 213- 220.
［24］ Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma［J］. Cancer, 2008, 113: 1614- 1622.
［25］ Herber S, Otto G, Schneider J, et al. Transarterial chemoembo- lization（TACE） for inoperable intrahepatic cholangiocarcinoma［J］. Cardiovasc Intervent Radiol, 2007, 30: 1156- 1165.
［26］ Ghiringhelli F, Lorgis V, Vincent J, et al. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second- line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience［J］. Chemotherapy, 2013, 59: 354- 360.
［27］ Mouli S, Memon K, Baker T, et al. Yttrium- 90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis［J］. J Vasc Interv Radiol, 2013, 24: 1227- 1234.
［28］ Al- Adra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium- 90 radioembolization: a systematic review and pooled analysis［J］. Eur J Surg Oncol, 2015, 41: 120- 127.
［29］ Zeng ZC, Tang ZY, Fan J, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients［J］. Cancer J, 2006, 12: 113- 122.
［30］ Ben- Josef E, Normolle D, Ensminger WD, et al. Phase Ⅱ trial of high- dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies［J］. J Clin Oncol, 2005, 23: 8739- 8747.
［31］ Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and toxicity using stereotactic body radiotherapy（SBRT） for advanced cholangiocarcinoma［J］. Radiat Oncol, 2012, 7: 67.
［32］ Lassen U, Jensen LH, Sorensen M, et al. A phase Ⅰ- Ⅱ dose escalation study of fixed- dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas［J］. Acta Oncol （Madr）, 2011, 50: 448- 454.
［33］ Leong E, Chen WW, Ng E, et al. Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma［J］. J Gastrointest Cancer, 2012, 43: 50- 55.
［34］ Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer［J］. N Engl J Med, 2010, 362: 1273- 1281.
［35］ Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary- tract cancer: a multicentre, open- label, randomised, phase 3 study［J］. Lancet Oncol, 2012, 13: 181- 188.
［36］ Berr F. Photodynamic therapy for cholangiocarcinoma［J］. Semin Liver Dis, 2004, 24: 177- 187.
［37］ 何英汉． 介入治疗肝内胆管细胞癌的疗效［J］． 中国老年学杂志， 2009， 29： 70- 72．
相似文献/References:
[1]杨熙章,吴纪瑞,杨永岩,等.灌注化疗预防肝癌术后复发[J].介入放射学杂志,1999,(02):32.
[2]许晓泉,施海彬,刘 圣,等. 外伤性颈动脉海绵窦瘘球囊栓塞术后复发危险因素分析及治疗[J].介入放射学杂志,2011,(12):931.
XU Xiao-quan,SHI Hai-bin,LIU Sheng,et al.The analysis of risk factors and the treatment of recurrent traumatic carotid cavernous fistulas previously managed with detachable balloons[J].journal interventional radiology,2011,(09):931.
[3]顾俊鹏,顾 朋,迪力木拉提?巴吾东,等. 大咯血的介入治疗及复发的影响因素分析[J].介入放射学杂志,2012,(11):952.
GU Jun? peng,GU Peng,DilimulatiBawudong,et al. The interventional management of massive hemoptysis and the analysis of factors influencing its recurrence[J].journal interventional radiology,2012,(09):952.
[4]胡 萍,司同国,郭 志.血清高迁移率族蛋白B1检测在T3N0M0期前列腺癌冷冻治疗后复发中的意义[J].介入放射学杂志,2013,(04):298.
HU Ping,SI Tong? guo,GUO Zhi..The significance of serum HMGB1 in forecasting the recurrence of stage T3N0M0 prostate cancer after cryotherapy[J].journal interventional radiology,2013,(09):298.
[5]徐国斌,易广新,熊斌,等.原发性肝癌术后早期肝内复发转移36例的介入治疗[J].介入放射学杂志,2013,(04):325.
XU Guo? bin,YI Guang? xin,XIONG Bin,et al.Interventional treatment of early intrahepatic recurrence or metastasis of primary liver carcinoma after surgical resection： initial experience of 36 cases[J].journal interventional radiology,2013,(09):325.
[6]任国荣,姜 平,曹枭强,等. 基于CT的三维颈内动脉瘤手术前后的血流动力学分析[J].介入放射学杂志,2013,(10):825.
REN Guo? rong,JIANG Ping,CAO Xiao? qiang,et al. Hemodynamic analysis of preoperative and postoperative carotid aneurysm by using CT 3- D numerical simulation[J].journal interventional radiology,2013,(09):825.
[7]宗迎迎,徐 浩,许 伟,等.经肝动脉化疗栓塞联合经皮微波消融序贯治疗早期肝癌的疗效及预后影响因素[J].介入放射学杂志,2015,(03):210.
ZONG Ying ying,XU Hao,XU Wei,et al.Sequential therapy of TACE followed by percutaneous microwave coagulation for early stage primary hepatocellular carcinomas： curative effect and prognostic factors[J].journal interventional radiology,2015,(09):210.
[8]任 炜,杨 薇.射频消融治疗复发性肝癌疗效及预后因素分析[J].介入放射学杂志,2015,(10):923.
REN Wei,YANG Wei.Radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma： analysis of the therapeutic results and prognostic factors[J].journal interventional radiology,2015,(09):923.
[9]李婉慈,朱晓黎,王万胜,等.中晚期肝内胆管细胞癌介入治疗的临床疗效分析[J].介入放射学杂志,2016,(09):813.
LI Wan- ci,ZHU Xiao- li,WANG Wan- sheng,et al.Clinical curative effect analysis of interventional therapy for advanced intrahepatic cholangiocarcinomas[J].journal interventional radiology,2016,(09):813.
[10]王 猛,魏 宁,徐 浩,等.腰椎间盘突出症臭氧消融术后短期内复发的危险因素[J].介入放射学杂志,2016,(11):977.
WANG Meng,WEI Ning,XU Hao,et al.Risk factors for the short- term recurrence of protrusion of lumbar intervertebral disc after ozone ablation[J].journal interventional radiology,2016,(09):977.
[11]徐中琪,甘 伟,刘 晟,等.经皮热消融治疗术后复发型肝内胆管细胞癌疗效分析[J].介入放射学杂志,2016,(11):973.
XU Zhong- qi,GAN Wei,LIU Sheng,et al.Percutaneous thermal ablation for the treatment of recurrent intrahepatic cholangio carcinoma： analysis of curative effect[J].journal interventional radiology,2016,(09):973.